Positron Emission Tomography of Infection and Vasculitis

Positron Emission Tomography of Infection and Vasculitis (PETU)

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01878721

Acronym

PETU

Enrollment

117

Registered

2013-06-17

Start date

2011-01-31

Completion date

2021-10-31

Last updated

2021-10-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infection, Vasculitis

Keywords

PET/CT, infection, vasculitis

Brief summary

The purpose of this study is to evaluate the value of positron emission tomography/computed tomography in various inflammatory conditions caused by bacterial infection or vasculitis. Glucose analog FDG is sensitive to detect inflammation foci but we hypothesize that other imaging agents such as PK11195 and Ga-citrate may have added value in certain applications.

Detailed description

The purpose of this study is to evaluate the value of PET/CT in various inflammatory conditions caused by bacterial infection or vasculitis. Our aim is to: 1. investigate whether FDG (18F-2-fluoro-2-deoxy-D-glucose fluorodeoxyglucose) PET/CT and 68Ga-(Gallium-68) citrate PET/CT enable the early and accurate detection of metastatic infection foci in Staphylococcus aureus bacteremia. 2. study the usefulness of FDG PET/CT in detection of endovascular infection in bacteremia caused by Salmonella spp. 3. find an optimal FDG PET/CT protocol for detection of infectious endocarditis and metastatic infection foci related to endocarditis. 4. study the value of FDG PET/CT in the diagnosis of infection of pacemaker or implantable cardioverter defibrillator. 5. investigate the usefulness of FDG PET/CT, 68Ga-citrate PET/CT, and 11C- (carbon-11) translocator protein ligand (PK11195) PET/CT in diagnosis of vasculitis and in imaging of the magnitude of the vascular changes.

Interventions

RADIATIONPET/CT

positron emission tomography/computed tomography

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Adults with * Staphylococcus aureus bacteremia or * Salmonella spp. bacteremia or * infective endocarditis or * infection of pacemaker or implantable cardioverter defibrillator or * vasculitis

Exclusion criteria

* underage, pregnant, breastfeeding, handicapped or prisoner

Design outcomes

Primary

Measure	Time frame
Detection of infection or vasculitis in PET images	within 1 week after starting the treatment

Secondary

Measure	Time frame
Standardized uptake value of PET imaging agent at the site of infection or vasculitis	within 1 week after starting the treatment

Countries

Finland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026